Nuvectis Pharma, Inc. (NASDAQ:NVCT) Major Shareholder Purchases $1,200,000.00 in Stock

Nuvectis Pharma, Inc. (NASDAQ:NVCT) major shareholder Marlio Charles Mosseri purchased 240,000 shares of the stock in a transaction that occurred on Friday, February 7th. The shares were purchased at an average cost of $5.00 per share, for a total transaction of $1,200,000.00. Following the completion of the acquisition, the insider now directly owns 2,884,121 shares of the company’s stock, valued at $14,420,605. This represents a 9.08 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s stock are required to disclose their sales and purchases with the SEC.

Marlio Charles Mosseri also recently made the following trade(s):

• On Friday, December 13th, Marlio Charles Mosseri acquired 17,000 shares of Nuvectis Pharma stock. The stock was purchased at an average price of $4.70 per share, with a total value of $79,900.00.

Nuvectis Pharma Stock Up 9.1 %

Shares of Nuvectis Pharma stock opened at $6.86 on Thursday. Nuvectis Pharma, Inc. has a twelve month low of $4.44 and a twelve month high of $12.10. The business has a 50-day moving average price of $5.70 and a 200 day moving average price of $6.34. The firm has a market cap of $132.54 million, a PE ratio of -5.91 and a beta of 0.22.

Institutional Inflows and Outflows

Large investors have recently made changes to their positions in the business. Nations Financial Group Inc. IA ADV purchased a new stake in Nuvectis Pharma in the 3rd quarter worth $63,000. Baxter Bros Inc. grew its position in shares of Nuvectis Pharma by 20.0% in the fourth quarter. Baxter Bros Inc. now owns 15,000 shares of the company’s stock valued at $81,000 after purchasing an additional 2,500 shares during the period. Oppenheimer & Co. Inc. purchased a new stake in shares of Nuvectis Pharma during the fourth quarter worth about $135,000. GSA Capital Partners LLP raised its position in shares of Nuvectis Pharma by 3.7% during the 3rd quarter. GSA Capital Partners LLP now owns 50,129 shares of the company’s stock worth $315,000 after purchasing an additional 1,790 shares during the last quarter. Finally, Forbes J M & Co. LLP lifted its stake in Nuvectis Pharma by 21.9% in the 4th quarter. Forbes J M & Co. LLP now owns 59,000 shares of the company’s stock valued at $319,000 after buying an additional 10,599 shares in the last quarter. 96.77% of the stock is owned by institutional investors and hedge funds.

Nuvectis Pharma Company Profile

Nuvectis Pharma, Inc, a biopharmaceutical company, focuses on the development of precision medicines for the treatment of serious unmet medical needs in oncology. The company's lead product candidate is NXP800, a novel small molecule that is in Phase 1b clinical trials for the treatment of patients with platinum-resistant, ARID1a-mutated ovarian carcinoma.